For the quarter ending 2025-09-30, BRGX had $491 increase in cash & cash equivalents over the period. -$77,564 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -80,565 | -445,199 |
| Depreciation and amortization | 12,376 | 49,754 |
| Amortization of debt discounts | 1,976 | 319 |
| Fair value of options issued to officers and directors for services | 0 | 0 |
| Fair value of common shares issued for services | 80,915 | 173,106 |
| Interest capitalized to debt balance | 4,033 | 6,759 |
| Fair value of common shares issued as loan incentives | 0 | 5,900 |
| Fair value of warrants issued for refunds | 0 | - |
| Accounts receivable | 41,495 | 6,123 |
| Inventories | -24,852 | 23,136 |
| Prepaid expenses and other assets | 6,446 | -75,533 |
| Accounts payable | -109,148 | 141,321 |
| Accounts payable - related parties | 61,399 | 110,585 |
| Accrued expenses and other liabilities | -24,896 | -47,465 |
| Accrued interest - related parties | 34,835 | 71,399 |
| Deferred revenue | -29,400 | -71,853 |
| Net cash used in operating activities | -71,564 | 40,900 |
| Purchases of property and equipment | 6,000 | 0 |
| Purchases of intangibles | 0 | 50,000 |
| Cash acquired in docsun transaction | 0 | 0 |
| Net cash used in investing activities | -6,000 | -50,000 |
| Note and loan payments | 46,674 | 23,592 |
| Increase in note and loan balances | 117,507 | 30,000 |
| Increase in note and loan balances - related parties | 0 | 0 |
| Net cash provided by financing activities | 70,833 | 6,408 |
| Net effect of exchange rate fluctuations | 7,222 | -9,256 |
| Net decrease in cash and cash equivalents | 491 | -11,948 |
| Cash and cash equivalents at beginning of period | 58,404 | - |
| Cash and cash equivalents at end of period | 46,947 | - |
BIOREGENX, INC. (BRGX)
BIOREGENX, INC. (BRGX)